Abstract: Systems and methods for invalidating and regenerating pages. In one embodiment, a method can include detecting content changes in a content database including various objects. The method can include causing an invalidation generator to generate an invalidation based on the modification and communicating the invalidation to a dependency manager. A cache manager can be notified that pages in a cache might be invalidated based on the modification via a page invalidation notice. In one embodiment, a method can include receiving a page invalidation notice and sending a page regeneration request to a page generator. The method can include regenerating the cached page. The method can include forwarding the regenerated page to the cache manager replacing the cached page with the regenerated page. In one embodiment, a method can include invalidating a cached page based on a content modification and regenerating pages which might depend on the modified content.

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9.

Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

Abstract: Systems and methods for invalidating and regenerating pages. In one embodiment, a method can include detecting content changes in a content database including various objects. The method can include causing an invalidation generator to generate an invalidation based on the modification and communicating the invalidation to a dependency manager. A cache manager can be notified that pages in a cache might be invalidated based on the modification via a page invalidation notice. In one embodiment, a method can include receiving a page invalidation notice and sending a page regeneration request to a page generator. The method can include regenerating the cached page. The method can include forwarding the regenerated page to the cache manager replacing the cached page with the regenerated page. In one embodiment, a method can include invalidating a cached page based on a content modification and regenerating pages which might depend on the modified content.

Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.

Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.

Abstract: Novel antibodies and their fragments are disclosed that specifically bind to CD4. Anti-CD4 antibodies are disclosed having amino acid substitutions in the hinge region that prevent intrachain disulfide bond formation resulting in antibody molecules with surprisingly improved bivalent stability. Increased stability facilitates manufacturing and provides increased in vivo stability. Antibodies are also disclosed that have amino acid substitutions that reduce binding to Fc receptor and ADCC activity that also result in a surprising effect on CD4 internalization. In addition, genes for such antibodies are disclosed that have been modified such that they have increased expression over their unmodified counterparts.

Abstract: Embodiments disclosed herein utilize statistical approximations to manage large filesystem-based caches based on imperfect information. When removing entries from a large cache, which may have a million or more entries, the cache manager does not need to find the absolutely oldest entry that has been accessed the least recently. Instead, it suffices to find an entry that is older than most. In embodiments disclosed herein, statistical sampling of the cache is performed to produce models of different properties of the cache, including the number of entries, distribution of access times, distribution of entry sizes, etc. The models are then used to guide decisions that involve those properties. The size of the samples can be adjusted to balance the cost of acquiring the samples against the confidence level of the models produced by the samples. To achieve randomness, entries are stored using prefixes of addresses generated via a message-digest function.

Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.

Abstract: Systems and methods for invalidating and regenerating pages. In one embodiment, a method can include detecting content changes in a content database including various objects. The method can include causing an invalidation generator to generate an invalidation based on the modification and communicating the invalidation to a dependency manager. A cache manager can be notified that pages in a cache might be invalidated based on the modification via a page invalidation notice. In one embodiment, a method can include receiving a page invalidation notice and sending a page regeneration request to a page generator. The method can include regenerating the cached page. The method can include forwarding the regenerated page to the cache manager replacing the cached page with the regenerated page. In one embodiment, a method can include invalidating a cached page based on a content modification and regenerating pages which might depend on the modified content.

Abstract: The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that bind to and inhibit CD14 pathway components, such as CD14 and LPS. The invention also relates to methods of treating subjects suffering from sepsis comprising administering these compositions, as well as kits for supplying the compositions for treatment.

Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies. The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.

Abstract: Systems and methods for invalidating and regenerating pages. In one embodiment, a method can include detecting content changes in a content database including various objects. The method can include causing an invalidation generator to generate an invalidation based on the modification and communicating the invalidation to a dependency manager. A cache manager can be notified that pages in a cache might be invalidated based on the modification via a page invalidation notice. In one embodiment, a method can include receiving a page invalidation notice and sending a page regeneration request to a page generator. The method can include regenerating the cached page. The method can include forwarding the regenerated page to the cache manager replacing the cached page with the regenerated page. In one embodiment, a method can include invalidating a cached page based on a content modification and regenerating pages which might depend on the modified content.